Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Breast Neoplasms 77Multiple Myeloma 40Lymphoma, Large B-Cell, Diffuse 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 37Lymphoma 37Lymphoma, Non-Hodgkin 27Leukemia 26Leukemia, Lymphocytic, Chronic, B-Cell 18Burkitt Lymphoma 18Recurrence 17Lymphoma, Mantle-Cell 17Lymphoma, Follicular 17Neoplasms, Plasma Cell 16Lymphoma, B-Cell 16Leukemia, Myeloid, Acute 16Neuroblastoma 12Hodgkin Disease 12Lymphoma, Large-Cell, Immunoblastic 11Myelodysplastic Syndromes 9Lymphoma, T-Cell, Peripheral 9Lymphoma, B-Cell, Marginal Zone 9Inflammatory Breast Neoplasms 9Triple Negative Breast Neoplasms 8Sarcoma 8Ovarian Neoplasms 8Immunoblastic Lymphadenopathy 7Neoplasm Metastasis 6Melanoma 6Leukemia, Myeloid, Chronic-Phase 6Hematologic Neoplasms 6

Interventions

seclidemstat 2Topotecan 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Histiocytoma, Angiomatoid Fibrous × Cyclophosphamide × Clear all
NCT03600649 2023-11-21

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Salarius Pharmaceuticals, LLC

Phase 1 Unknown
50 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibroma, Myoepithelioma, Sarcoma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

NCT05266196 2023-08-01

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Salarius Pharmaceuticals, LLC

Phase 1/2 Unknown
10 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Myoepithelioma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡